Doorgaan naar hoofdcontent

Human medicines European public assessment report (EPAR): IntronA, interferon alfa-2b, Carcinoid Tumor,Leukemia, Hair...

 

 
 
Human medicines European public assessment report (EPAR): IntronA, interferon alfa-2b, Carcinoid Tumor,Leukemia, Hairy Cell,Lymphoma, Follicular,Hepatitis B, Chronic,Hepatitis C, Chronic,Leukemia, Myelogenous, Chronic, BCR-ABL Positive,Melanoma,Multiple
Human medicines European public assessment report (EPAR): IntronA, interferon alfa-2b, Carcinoid Tumor,Leukemia, Hairy Cell,Lymphoma, Follicular,Hepatitis B, Chronic,Hepatitis C, Chronic,Leukemia, Myelogenous, Chronic, BCR-ABL Positive,Melanoma,Multiple Myeloma, Date of authorisation: 09/03/2000, Revision: 34, Status: Authorised



 
 
Integration Science into Everyday Practice Conference



 
 
Human medicines European public assessment report (EPAR): Praxbind, idarucizumab, Hemorrhage, Date of authorisation: 20/11/2015, Revision: 10, Status: Authorised
Human medicines European public assessment report (EPAR): Praxbind, idarucizumab, Hemorrhage, Date of authorisation: 20/11/2015, Revision: 10, Status: Authorised


Actueel zorgnieuws in jouw mailbox ontvangen?
Direct het hele artikel lezen? Meld je aan voor de nieuwsbrief.